Ryutaro Asano Selected Research

ErbB Receptors (EGF Receptor)

12/2023	Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
11/2023	Incorporation of a repeated polypeptide sequence in therapeutic antibodies as a universal masking procedure: A case study of T cell-engaging bispecific antibodies.
11/2021	Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
11/2020	Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
1/2017	A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.
1/2015	[Functionalization of Bispecific Therapeutic Antibodies Based on Protein Engineering].
10/2013	Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers.
2/2013	Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy.
1/2012	Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.
10/2011	Electrochemical detection of receptor-mediated endocytosis by scanning electrochemical microscopy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryutaro Asano Research Topics

Disease

33	Neoplasms (Cancer) 12/2023 - 03/2002
5	Carcinoma (Carcinomatosis) 07/2006 - 03/2002
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 03/2024
1	Inflammation (Inflammations) 03/2024
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2018
1	Infections 04/2011
1	Burkitt Lymphoma (Burkitt's Lymphoma) 10/2007
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 10/2007
1	Lymphoma (Lymphomas) 10/2007
1	Leukemia 10/2007
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2007

Drug/Important Bio-Agent (IBA)

16	ErbB Receptors (EGF Receptor)IBA 12/2023 - 04/2009
12	Bispecific AntibodiesIBA 12/2023 - 03/2002
8	AntibodiesIBA 12/2023 - 06/2004
5	Proteins (Proteins, Gene)FDA Link 03/2024 - 03/2002
5	AntigensIBA 11/2021 - 03/2002
5	Immunoglobulin G (IgG)IBA 01/2014 - 09/2007
4	Interleukin-2 (IL2)IBA 07/2006 - 03/2002
4	Indicators and Reagents (Reagents)IBA 07/2006 - 03/2002
3	Single-Chain AntibodiesIBA 11/2023 - 03/2002
2	Peptide Hydrolases (Proteases)FDA Link 11/2023 - 01/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 06/2004
2	CytokinesIBA 01/2021 - 03/2005
2	Interferon-gamma (Interferon, gamma)IBA 01/2021 - 02/2003
2	Immunoglobulin FragmentsIBA 10/2013 - 07/2010
2	Membrane Proteins (Integral Membrane Proteins)IBA 10/2011 - 04/2009
2	interleukin-21 (interleukin 21)IBA 10/2007 - 09/2002
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2004 - 02/2003
2	SuperantigensIBA 03/2002 - 03/2002
1	KetonesIBA 03/2024
1	EnzymesIBA 03/2024
1	Biomarkers (Surrogate Marker)IBA 03/2024
1	C-Reactive ProteinIBA 03/2024
1	Glucose 1-DehydrogenaseIBA 03/2024
1	Therapeutic UsesIBA 11/2021
1	Granzymes (Granzyme)IBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 12/2018
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2017
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 02/2013
1	GoldIBA 09/2012
1	Cetuximab (Erbitux)FDA Link 10/2011
1	Fc Receptors (Fc Receptor)IBA 10/2011
1	Epidermal Growth Factor (EGF)IBA 04/2011
1	Interleukin-21 ReceptorsIBA 10/2007
1	Immunoglobulin Variable RegionIBA 03/2005
1	Interleukin-12 (IL 12)IBA 03/2005
1	Glycoproteins (Glycoprotein)IBA 03/2002
1	Recombinant Fusion ProteinsIBA 03/2002

Therapy/Procedure

14	Immunotherapy 11/2021 - 03/2002
7	Therapeutics 11/2021 - 03/2002